Paula Soteropoulos Sells 6,000 Shares of uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QUREGet Rating) Director Paula Soteropoulos sold 6,000 shares of the business’s stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $22.59, for a total transaction of $135,540.00. Following the completion of the transaction, the director now owns 16,382 shares in the company, valued at approximately $370,069.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Paula Soteropoulos also recently made the following trade(s):

  • On Tuesday, December 13th, Paula Soteropoulos sold 3,000 shares of uniQure stock. The shares were sold at an average price of $23.45, for a total transaction of $70,350.00.
  • On Tuesday, November 29th, Paula Soteropoulos sold 6,200 shares of uniQure stock. The shares were sold at an average price of $25.38, for a total transaction of $157,356.00.

uniQure Trading Up 3.0 %

NASDAQ:QURE opened at $21.89 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 7.26 and a quick ratio of 7.20. The firm has a 50-day moving average of $23.25 and a 200-day moving average of $21.46. The company has a market cap of $1.02 billion, a PE ratio of -8.14 and a beta of 1.10. uniQure has a one year low of $12.52 and a one year high of $28.25.

uniQure (NASDAQ:QUREGet Rating) last posted its earnings results on Wednesday, November 2nd. The biotechnology company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.09. uniQure had a negative net margin of 204.12% and a negative return on equity of 24.47%. The company had revenue of $1.45 million during the quarter, compared to the consensus estimate of $10.70 million. As a group, equities research analysts expect that uniQure will post -3.57 EPS for the current fiscal year.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in uniQure by 14.0% in the 3rd quarter. BlackRock Inc. now owns 4,898,640 shares of the biotechnology company’s stock worth $91,897,000 after purchasing an additional 599,805 shares in the last quarter. Point72 Asset Management L.P. grew its position in uniQure by 11.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 4,259,886 shares of the biotechnology company’s stock worth $79,915,000 after purchasing an additional 440,186 shares in the last quarter. State Street Corp grew its position in uniQure by 29.5% in the 3rd quarter. State Street Corp now owns 3,063,265 shares of the biotechnology company’s stock worth $57,467,000 after purchasing an additional 698,121 shares in the last quarter. PFM Health Sciences LP grew its position in uniQure by 7.0% in the 3rd quarter. PFM Health Sciences LP now owns 2,393,311 shares of the biotechnology company’s stock worth $44,899,000 after purchasing an additional 156,941 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in uniQure by 10.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,434,004 shares of the biotechnology company’s stock worth $26,903,000 after purchasing an additional 141,382 shares in the last quarter. 88.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

QURE has been the topic of several recent analyst reports. The Goldman Sachs Group boosted their target price on shares of uniQure from $47.00 to $57.00 and gave the company a “buy” rating in a report on Wednesday, November 23rd. Truist Financial lifted their price target on shares of uniQure from $51.00 to $65.00 in a research note on Wednesday, November 23rd. William Blair reaffirmed an “outperform” rating on shares of uniQure in a research note on Wednesday, November 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research note on Thursday, November 3rd. Finally, StockNews.com initiated coverage on shares of uniQure in a research note on Wednesday, October 12th. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average price target of $47.17.

About uniQure

(Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

See Also

Insider Buying and Selling by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.